Evidence map›Paper›PMID 40042755›Full record

ArticleBiochemical genetics2026

Pan-Cancer Analysis of ANO6 and Experimental Validation in Metastatic Melanoma.

Yao An, Haoran Dong, Meishan Yan, Caixu Liu, Danfeng Hu, Qi Liu, Jingqiu Zhang, Xu Han, Zimeng Li, Minghui Xu and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Biochemical genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Yao AnDepartment of Medical Laboratory Science and Technology, Harbin Medical University-Daqing, Daqing, 163000, China.
Haoran DongDepartment of Medical Laboratory Science and Technology, Harbin Medical University-Daqing, Daqing, 163000, China.
Meishan YanDepartment of Medical Laboratory Science and Technology, Harbin Medical University-Daqing, Daqing, 163000, China.
Caixu LiuDepartment of Medical Laboratory Science and Technology, Harbin Medical University-Daqing, Daqing, 163000, China.
Danfeng HuDepartment of Medical Laboratory Science and Technology, Harbin Medical University-Daqing, Daqing, 163000, China.
Qi LiuDepartment of Medical Laboratory Science and Technology, Harbin Medical University-Daqing, Daqing, 163000, China.
Jingqiu ZhangDepartment of Medical Laboratory Science and Technology, Harbin Medical University-Daqing, Daqing, 163000, China.
Xu HanDepartment of Medical Laboratory Science and Technology, Harbin Medical University-Daqing, Daqing, 163000, China.
Zimeng LiDepartment of Medical Laboratory Science and Technology, Harbin Medical University-Daqing, Daqing, 163000, China.
Minghui XuDepartment of Medical Laboratory Science and Technology, Harbin Medical University-Daqing, Daqing, 163000, China.
Li ChenDepartment of Medical Laboratory Science and Technology, Harbin Medical University-Daqing, Daqing, 163000, China.
Quanzhi ZhangDepartment of Medical Laboratory Science and Technology, Harbin Medical University-Daqing, Daqing, 163000, China.
Chunyan GaoDepartment of Medical Laboratory Science and Technology, Harbin Medical University-Daqing, Daqing, 163000, China. gaochunyan1234@163.com.

Funding

Marshal Initiative Funding HMUMIF-22005National Natural Science Foundation of China 82070140Natural Science Foundation of Heilongjiang Province LH2021H023
6 · The paper itself

Abstract

Anoctamin 6 (ANO6) has been implicated in the oncogenicity of malignancies. However, pan-cancer analysis of ANO6 to fully explore its role in tumors has not been performed and little is reported on its role in melanoma. The ANO6 expression levels, clinical correlation, prognostic significance, mutational profiles, immune infiltration pattern, immune checkpoints, immunomodulatory genes, tumor heterogeneity, and molecular function were explored via systematic bioinformatics analysis and multiple public databases. Subsequently, the biological functions of ANO6 in the pulmonary metastasis of B16F10 melanoma cells in vivo were assessed by experimental validation. Our findings have demonstrated that ANO6 was highly expressed in most cancers and associated with poorer prognosis in cancer patients. A close relationship was observed between ANO6 expression level and clinicopathological characteristics, tumor immunity, and tumor heterogeneity. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses indicated that ANO6 was associated with immune response and regulated many cancer-related pathways. Furthermore, a melanoma pulmonary metastasis mice model showed that ANO6 was overexpressed in lung metastasis tissues compared with corresponding normal tissues. Collectively, ANO6 may serve as reliable biomarkers to predict the prognosis for diverse types of cancer and as a prospective marker for melanoma progression.

Indexed as

AnoctaminsBiomarkers, TumorLung NeoplasmsMelanomaAnimalsCell Line, TumorFemaleGene Expression Regulation, NeoplasticHumansMaleMiceMice, Inbred C57BLNeoplasm MetastasisPrognosisAnoctaminsBiomarkers, TumorANO6MelanomaPan-cancer analysisPrognosisTumor immunity

Identifiers

PMID40042755

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.